Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 2/20 | 0.64 |
| ▸ | DRD2 | P14416 | 1/20 | 0.61 |
| ▸ | DRD3 | P35462 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | GPR183 | P32249 | 1/20 | 0.59 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.59 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.58 |
| ▸ | GHSR | Q92847 | 2/20 | 0.56 |
| ▸ | FASN | P49327 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | KDR | P35968 | 1/20 | 0.55 |
| ▸ | MGLL | Q99685 | 1/20 | 0.55 |
| ▸ | NUDT15 | Q9NV35 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16002856 | 0.90 | GHSR (0.69) | MAPK14DRD2DRD3HPGDTSHR | |
| SCHEMBL22216445 | 0.87 | MAPK14 (0.64) | MAPK14DRD2DRD3GPR183GHSR | |
| SCHEMBL30226931 | 0.87 | MAPK14 (0.64) | MAPK14DRD2DRD3HPGDGPR183 | |
| SCHEMBL30329646 | 0.87 | MAPK14 (0.64) | MAPK14DRD2DRD3GPR183GHSR | |
| SCHEMBL8534513 | 0.87 | MAPK14 (0.64) | MAPK14DRD2DRD3HPGDGPR183 | |
| SCHEMBL2214616 | 0.85 | MAPK14 (0.63) | MAPK14DRD2DRD3HPGDGPR183 | |
| SCHEMBL29944365 | 0.85 | MAPK14 (0.63) | MAPK14DRD2DRD3HPGDGPR183 | |
| SCHEMBL3457123 | 0.85 | MAPK14 (0.63) | MAPK14DRD2DRD3HPGDGPR183 | |
| SCHEMBL2219560 | 0.85 | MAPK14 (0.60) | MAPK14DRD2DRD3GPR183GHSR | |
| SCHEMBL3385466 | 0.85 | MAPK14 (0.60) | MAPK14DRD2DRD3HPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9328125-B2 | Bivalent AMPA receptor positive allosteric modulators | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-05-03 | — | — | US | disclosed |
| US-9328125-B2 | Bivalent AMPA receptor positive allosteric modulators | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-05-03 | — | — | US | disclosed |
| US-20150057248-A1 | BIVALENT AMPA RECEPTOR POSITIVE ALLOSTERIC MODULATORS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-02-26 | — | — | US | disclosed |
| US-20150057248-A1 | BIVALENT AMPA RECEPTOR POSITIVE ALLOSTERIC MODULATORS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-02-26 | — | — | US | disclosed |
| WO-2013130501-A1 | BIVALENT AMPA RECEPTOR POSITIVE ALLOSTERIC MODULATORS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-09-06 | — | — | WO | disclosed |
| US-8470830-B2 | 5-(heterocyclyl)alkyl-N-(arylsulfonyl)indole compounds and their use as 5-HT6 ligands | SUVEN LIFE SCIENCES LIMITED (IN) | 2013-06-25 | — | — | US | disclosed |
| CN-101553467-B | 5-(heterocyclyl)alkyl-N-(arylsulfonyl)indole compounds and their use as 5-HT6 ligands | SUVEN LIFE SCIENCES LTD. (IN) | 2011-12-07 | — | — | CN | disclosed |
| EP-2114878-B1 | 5-(HETEROCYCLYL)ALKYL-N-(ARYLSULFONYL)INDOLE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS | SUVEN LIFE SCIENCES LTD (IN) | 2010-12-15 | — | — | EP | disclosed |
| US-7745641-B2 | Nitrogen-containing heterocyclic compound | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-06-29 | — | — | US | disclosed |
| US-20100041673-A1 | 5-(HETEROCYCLYL)ALKYL-N-(ARYLSULFONYL)INDOLE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS | SUVEN LIFE SCIENCES LIMITED (IN) | 2010-02-18 | — | — | US | disclosed |
| EP-2114878-A1 | 5-(HETEROCYCLYL)ALKYL-N-(ARYLSULFONYL)INDOLE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS | Suven Life Sciences Limited (IN) | 2009-11-11 | — | — | EP | disclosed |
| EP-2108642-A1 | JAK INHIBITOR | Kyowa Hakko Kirin Co., Ltd. (JP) | 2009-10-14 | — | — | EP | disclosed |
| CN-101553467-A | 5-(heterocyclyl)alkyl-N-(arylsulfonyl)indole compounds and their use as 5-HT6 ligands | SUVEN LIFE SCIENCES LTD (IN) | 2009-10-07 | — | — | CN | disclosed |
| US-20090054407-A1 | Nitrogen-containing heterocyclic compound | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-02-26 | — | — | US | disclosed |
| WO-2008084492-A1 | 5-(HETEROCYCLYL)ALKYL-N-(ARYLSULFONYL)INDOLE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS | SUVEN LIFE SCIENCES LIMITED (IN) | 2008-07-17 | — | — | WO | disclosed |
| EP-1880993-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2008-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054407-A1 | Nitrogen-containing heterocyclic compound | NR4A1, NR5A2, PRMT8 | MAPK14 1841/4885DRD2 311/4885DRD3 170/4885 |
| US-20100041673-A1 | 5-(HETEROCYCLYL)ALKYL-N-(ARYLSULFONYL)INDOLE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS | HTR6, HTR5A, HTR2C | MAPK14 2038/4885DRD2 85/4885DRD3 214/4885 |
| US-20150057248-A1 | BIVALENT AMPA RECEPTOR POSITIVE ALLOSTERIC MODULATORS | GRIK2, GABRE, GRIK4 | MAPK14 3269/4885DRD2 861/4885DRD3 1073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.